Home » Newsletters » BioWorld Science

BioWorld Science

April 23, 2014

View Archived Issues

Determination of the origin of bacterial lung infections in animal models of cystic fibrosis

Safety, immunogenicity and efficacy of DCVAC/PCa vaccine in recurrent prostate cancer

CRLX-522 leads to reduction of tumor growth in vivo

Novel PI3K-p110beta/delta inhibitor demonstrates potent antitumor efficacy in vivo

Novel cancer vaccine combined with cyclophosphamide shows potential in a phase I trial

NGM-282 shows promise in early clinical and preclinical studies

Dicerna drug is first Dicer-substrate siRNA to enter clinical trials

Alethia develops antibody-drug conjugate targeting KAAG1 for cancer

AbbVie submits NDA to FDA for all-oral, interferon-free therapy for HCV

NIH to support phase II trial of 3K3A-APC in stroke

Sentinel Oncology and Oncothyreon to develop and commercialize Chk1 inhibitors

Karyopharm initiates pediatric phase I trial of selinexor

Evoke Pharma begins phase III trial of EVK-001 for diabetic gastroparesis

New PKCiota inhibitors for cancer disclosed by Cancer Research Technology and Cephalon

Adcetris now available in Japan for Hodgkin's lymphoma or anaplastic large cell lymphoma

Japanese scientists present novel glucokinase activators

FDA accepts refiling of cobicistat and elvitegravir NDAs for HIV

Incruse Ellipta approved in Canada for COPD

Merck & Co. synthesizes novel GPR119 receptor agonists

Merck KGaA designs new vanin-1 inhibitors for inflammatory disorders

Revance Therapeutics reports data from phase I/II study of RT-002

Cubist Pharmaceuticals submits NDA to FDA for ceftolozane/tazobactam

Biogen Idec licenses Amunix's Factor VIII product

Aastrom Biosciences to acquire Sanofi's Cell Therapy and Regenerative Medicine business

GlaxoSmithKline and Novartis make major restructuring deal

FDA advisory committee recommends against approval of MoxDuo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...